Figure 1.

(A) Individual patient HVPG data following treatment with Infliximab are plotted against time. HVPG was measured 48 hours before (day –2) and 24 hours after (day 1) treatment with Infliximab, and then after a mean discharge interval period of 19 (4) days. A significant reduction (p<0.001) was noted by day 1 in all but one patient (who entered the study with a low baseline HVPG), with a sustained reduction by the day of discharge (p<0.001). (B) Individual patient CO (l/min) data with Infliximab treatment plotted against time. The broken lines represent the two patients in whom CO increased at day 1 or by the end of the study, respectively, despite reduction in their HVPG, as shown in (A).